Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes Mellitus

被引：198
作者：
Chen, W. -W. [1 ]
Li, L. [2 ,3 ]
Yang, G. -Y. [1 ]
Li, K. [1 ]
Qi, X. -Y. [1 ]
Zhu, W. [1 ]
Tang, Y. [4 ]
Liu, H. [5 ]
Boden, G. [6 ,7 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 2, Dept Endocrinol, Chongqing 400010, Peoples R China
[2] Chongqing Med Univ, Minist Educ, Dept Clin Biochem, Chongqing, Peoples R China
[3] Chongqing Med Univ, Minist Educ, Key Lab Lab Med Diagnost, Chongqing, Peoples R China
[4] Centocor Inc, Oncol Res, Malvern, PA 19355 USA
[5] Univ Mississippi, Med Ctr, Dept Pediat, Jackson, MS 39216 USA
[6] Temple Univ, Sch Med, Div Endocrinol Diabet Metab, Philadelphia, PA 19122 USA
[7] Temple Univ, Sch Med, Clin Res Ctr, Philadelphia, PA 19122 USA
来源：
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES | 2008年 / 116卷 / 01期
关键词：
FGF-21; insulin resistance; T2DM;
D O I：
10.1055/s-2007-985148
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Fibroplast growth factor (FGF-21) is a recently discovered metabolic regulator. Its pathophysiologic role in humans remains unknown. In this study, we have investigated whether or not plasma FGF-21 level was different in patients with type 2 diabetes mellitus (T2DM) and nondiabetic controls. We also assessed associations between plasma FGF-21 body composition and several metabolic parameters. Fasting FGF-21 levels were significantly increased in patients with T2DM compared with controls (1.82 +/- 0.65 vs. 1.53 +/- 0.60 mu g/L, P<0.05). In T2DM patients, fasting plasma FGF-21 correlate negatively with fasting blood glucose (r = -0.31, P< 0.05). Multiple regression analysis showed that FBG, plasma insulin and HOMA(IS) were independent influencing plasma FGF-21 levels. The present work suggests a potential role for FGF-21 in the pathogenesis of insulin resistance and T2DM.
引用
收藏
页码：65 / 68
页数：4
相关论文
共 15 条
[1]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[2]  
2-S
[3]  
Bhushan A, 2001, DEVELOPMENT, V128, P5109
[4]   Fibroblast growth factor 19 increases metabolic rate I and reverses dietary and leptlin-deficient diabetes [J].
Fu, L ;
John, LM ;
Adams, SH ;
Yu, XX ;
Tomlinson, E ;
Renz, M ;
Williams, PM ;
Soriano, R ;
Corpuz, R ;
Moffat, B ;
Vandlen, R ;
Simmons, L ;
Foster, J ;
Stephan, JP ;
Tsai, SP ;
Stewart, TA .
ENDOCRINOLOGY, 2004, 145 (06) :2594-2603
[5]   FGF-21 as a novel metabolic regulator [J].
Kharitonenkov, A ;
Shiyanova, TL ;
Koester, A ;
Ford, AM ;
Micanovic, R ;
Galbreath, EJ ;
Sandusky, GE ;
Hammond, LJ ;
Moyers, JS ;
Owens, RA ;
Gromada, J ;
Brozinick, JT ;
Hawkins, ED ;
Wroblewski, VJ ;
Li, DS ;
Mehrbod, F ;
Jaskunas, SR ;
Shanafelt, AB .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (06) :1627-1635
[6]   Reduced phosphorylation of transcription factor Elk-1 in cultured fibroblasts of a patient with premature aging syndrome and insulin resistance [J].
Knebel, B ;
Avci, H ;
Bullmann, C ;
Kotzka, J ;
Müller-Wieland, D .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (02) :94-101
[7]   Fibroblast growth factor-16 is a growth factor for embryonic brown adipocytes [J].
Konishi, M ;
Mikami, T ;
Yamasaki, M ;
Miyake, A ;
Itoh, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (16) :12119-12122
[8]   HOMEOSTASIS MODEL ASSESSMENT - INSULIN RESISTANCE AND BETA-CELL FUNCTION FROM FASTING PLASMA-GLUCOSE AND INSULIN CONCENTRATIONS IN MAN [J].
MATTHEWS, DR ;
HOSKER, JP ;
RUDENSKI, AS ;
NAYLOR, BA ;
TREACHER, DF ;
TURNER, RC .
DIABETOLOGIA, 1985, 28 (07) :412-419
[9]   Identification of a novel FGF, FGF-21, preferentially expressed in the liver [J].
Nishimura, T ;
Nakatake, Y ;
Konishi, M ;
Itoh, N .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2000, 1492 (01) :203-206
[10]   Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain [J].
Nishimura, T ;
Utsunomiya, Y ;
Hoshikawa, M ;
Ohuchi, H ;
Itoh, N .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1999, 1444 (01) :148-151
12